ReviewFrontiers in immunology2022
From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- AI models for the identification of prognostic and predictive biomarkers in lung cancer: a systematic review and meta-analysis.Frontiers in oncology · 2025Pooled it
- Prognostic value of PD-L1 expression in patients with anal cancer: a meta-analysis.Biomarkers in medicine · 2024Pooled it
- Review
- Article
- Exploring the immune landscape of melanoma of the lower female genital tract.Virchows Archiv : an international journal of pathology · 2026Article
- Deep learning-based non-invasive prediction of PD-L1 status and immunotherapy survival stratification in esophageal cancer using [European journal of nuclear medicine and molecular imaging · 2026Article
- Predictive capacity of mismatch repair status in the use of immune checkpoint inhibitors for the treatment of aggressive pituitary tumors and pituitary carcinomas: An illustrative case report and literature review.Surgical neurology international · 2026Article
- Pancreatic cancer immunotherapy biomarkers: from traditional markers to multimodal integration and dynamic monitoring.Frontiers in immunology · 2026Review
- Alternate actions of CDK4/6 inhibitors beyond cell cycle blockade: unexplored roles in therapy resistance.Cancer metastasis reviews · 2025Review
- Immunotherapy-Related Gastritis in Small Cell Lung Cancer Treatment With Durvalumab-A Case Report.Cancer reports (Hoboken, N.J.) · 2025Article
- Single-cell RNA sequencing identifies CD8Teff cell activation as a predictive biomarker in triple-negative breast cancer immunotherapy.Molecular biomedicine · 2025Article
- Expanding horizons in esophageal squamous cell carcinoma: The promise of induction chemoimmunotherapy with radiotherapy.World journal of clinical oncology · 2025Article
- MRI-based texture analysis for the evaluation of the response to neoadjuvant chemoimmunotherapy in locally advanced head and neck squamous cell carcinoma.BMC medical imaging · 2025Article
- Immuno-Oncology at the Crossroads: Confronting Challenges in the Quest for Effective Cancer Therapies.International journal of molecular sciences · 2025Review
- [German expert consensus on programmed cell death ligand 1 (PD-L1) testing in perioperative systemic therapy of muscle invasive bladder cancer].Urologie (Heidelberg, Germany) · 2024Review
- SPHK1 promotes bladder cancer metastasis via PD-L2/c-Src/FAK signaling cascade.Cell death & disease · 2024Article
- Engineered Immunologic Niche Monitors Checkpoint Blockade Response and Probes Mechanisms of Resistance.Immunomedicine · 2024Article
- ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1-Directed 4-1BB Activation.Cancer research · 2024Article
- PET imaging of PD-L1 with a small molecule radiotracer.European journal of nuclear medicine and molecular imaging · 2024Article
- Retreatment with Immune Checkpoint Inhibitors in the New Scenario of Immunotherapy in Non-Small Cell Lung Cancer.Cancers · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Developing biomarkers for accurately predicting the efficacy of immune checkpoint inhibitor (ICI) therapies is conducive to avoiding unwanted side effects and economic burden. At the moment, the quantification of programmed cell death ligand 1 (PD-L1) in tumor tissues is clinically used as one of the combined diagnostic assays of response to anti-PD-1/PD-L1 therapy. However, the current assays for evaluating PD-L1 remain imperfect. Recent studies are promoting the methodologies of PD-L1 evaluation from rough to precise. Standardization of PD-L1 immunohistochemistry tests is being promoted by using optimized reagents, platforms, and cutoff values. Combining novel
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.